These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20415778)

  • 21. [Reactivity of a natural human monoclonal polyreactive antibody with exogenous and endogenous antigens and its possible role in an idiotypic-anti-idiotypic network].
    Roggenbuck D; Kaufmann J; Franz J; Marx U; Schoenherr G; Jahn S; Porstmann T
    Z Arztl Fortbild (Jena); 1994 Aug; 88(7-8):485-9. PubMed ID: 7856249
    [No Abstract]   [Full Text] [Related]  

  • 22. Loading DCs with Ag.
    Vari F; Hart DN
    Cytotherapy; 2004; 6(2):111-21. PubMed ID: 15203987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of complement in autoimmune renal disease.
    Seelen MA; Daha MR
    Autoimmunity; 2006 Aug; 39(5):411-5. PubMed ID: 16923541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infections and autoimmune diseases.
    Bach JF
    J Autoimmun; 2005; 25 Suppl():74-80. PubMed ID: 16278064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [What is the role of autoimmune processes in nephropathies?].
    Ehrich JH; Oemar BS; Bruijn JA
    Monatsschr Kinderheilkd; 1990 Nov; 138(11):724-9. PubMed ID: 2290431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease.
    Barabas AZ; Cole CD; Barabas AD; Lafreniere R
    Biologics; 2007 Mar; 1(1):59-68. PubMed ID: 19707349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
    Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
    Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
    Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
    Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of autoantibody activities in sera anti-DNA antibody and circulating immune complexes from 12 systemic lupus erythematosus patients.
    Adyel FZ; Hentati B; Boulila A; Hachicha J; Ternynck T; Avrameas S; Ayadi H
    J Clin Lab Anal; 1996; 10(6):451-7. PubMed ID: 8951619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
    Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
    Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
    Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine.
    Milner RJ; Salute M; Crawford C; Abbot JR; Farese J
    Vet Immunol Immunopathol; 2006 Dec; 114(3-4):273-84. PubMed ID: 17027091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autoimmune disorders in diabetes.
    Boitard C; Debray-Sachs M; Bach JF
    Adv Nephrol Necker Hosp; 1986; 15():281-305. PubMed ID: 3082114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA vaccination: antigen presentation and the induction of immunity.
    Shedlock DJ; Weiner DB
    J Leukoc Biol; 2000 Dec; 68(6):793-806. PubMed ID: 11129646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.
    Wieckowski S; Baumgaertner P; Corthesy P; Voelter V; Romero P; Speiser DE; Rufer N
    J Immunol; 2009 Oct; 183(8):5397-406. PubMed ID: 19786555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autoimmune syndrome after induction of neonatal tolerance to alloantigens: effects of in vivo treatment with anti-T cell subset monoclonal antibodies.
    Merino J; Schurmans S; Luzuy S; Izui S; Vassalli P; Lambert PH
    J Immunol; 1987 Sep; 139(5):1426-31. PubMed ID: 3114366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.